I agree with you. Yet another red flag: The CEO's now-obscene $611K salary. Up from a mere $500K last year.
As for Pavco's departure, I was also surprised but she's 61 so maybe she decided the time to retire had arrived.
But there are some noteworthy near-term catalysts: Q4 readouts.
RXI-109 is due in early Q4 (Oct?). I, too, am very doubtful but we'll see.
Samcyprone - I expect good news
RXI-231 - Studies 1&2 (skin irritation & sensitization) successful. Study 3 (Pigmentation reduction) is due to start somewhere between early to mid September. I expect it to take no more than 1-2 months. IMO, this is important. IF good, RXI's money woes could be erased.
My wish list: RXI-185 (anti-collagenase) seems to have dropped off the radar. Last update was on the Q1 CC (March 30) - and only in the Q&A segment (ie, not in the prepared remarks). When asked about its status, was told that RXI is still trying to develop a topical formulation that penetrates deeply enough into the skin to affect the collagen.
News 
Market Data 
Discover 
